藥華醫藥6446-ESG企業永續,社會責任CSR,環境保護,TCFD,公司治理,SASB, AOP Orphan, FDA藥證,FDA查廠

Transform our Corporate Culture and Innovation
Facilitate Human health, well-being and Sustainability

Bold innovation, Rapid adaptation
Strong integrity, Sustainable development

2024 ESG Report

Transform innovative science into medical solutions that bring shared value to patients and facilitate human health and well-being.

Our Focuses

Corporate Governance

Drug Quality and Safety Management

Sustainable Environment

Fostering a Corporate Culture of Employee Well-Being

Contributors Participating in Society

Supplier Code of Conduct

EHS Policy

0

female directors

0

valid patents

0

% attendance at Audit Committee and Numeration Committee meetings

Highlights of Corporate Governance

PharmaEssentia strives to improve its cor-porate governance mechanisms and pursue sustainable operations. We continue to strengthen Board functions and governance structures, and actively optimize risk controls to prevent negative impacts from affecting corporate operations. We also attach great importance to information security and pro-tection of personal information, and work to maintain corporate information security and personal information of patients.

0

hours of Good Manufacturing Practice (GMP)/Good Distribution Practice (GDP) training

0

NT$ billion in R&D expenditures, an increase of 16% compared to 2023

0

post-marketing recalls

Highlights of Drug Quality and Safety Management

PharmaEssentia is focused on independently developed R&D technologies which not only represent breakthroughs in the biomedical industry, but also improve patient wellbeing. All stages from new drug R&D, production, manufacturing, transportation, and launch rigorously and comprehensively adhere to complex regulatory and quality requirements. To maximize the life cycles of core products, PharmaEssentia conducts constant patent mining and enables comprehensive protection for innovative R&D technologies and has established various intellectual property protection measures. We also manage post-marketing risks through continued monitoring and reporting of drug safety information as part of our responsibilities to protect patient interests.

0

% Environmental investment growth rate in 2024

0

％ Reduction in greenhouse gas emission intensity

0

％ Reduction in energy consumption intensity

Highlights of Sustainable Environment

PharmaEssentia pledges to min-imize negative environmental im-pacts during product production processes and life cycle stages. We established environmental health and safety policies as well as envi-ronmental management indicators that include future targets for waste intensity, energy intensity, and greenhouse gas emissions intensity; incorporated the Task Force on Cli-mate-Related Financial Disclosures (TCFD) framework to identify ma-terial climate risks & opportunities and formulate response measures; and regularly track progress on indi-cators and response measures.

0

% Proportion of female executives

0

+ hours Average training hours for each employee

0

+％ Employee welfare expenditures

Highlights of Fostering a Corporate Culture of Employee Well-Being

PharmaEssentia formulated human rights policies that adhere to inter-national human rights regulations to protect stakeholder interests, and works to build diverse and equal workplace environments where talent values and salaries are not affected by age, gender, race, or region. PharmaEssentia cultivates talent from three functional aspects (core values, management and leadership, and professional capa-bilities) using a dual-track diverse talent development framework to cultivate outstanding management and professional talents while low-ering talent shortage risks.

0

+ BESREMi cumulative global patients usage since launch

0

Number of patients benefiting from compassionate treatment

0

Total number of clinical trial patients worldwide

Highlights of Contributors Participating in Society

We utilized our core advantages and focused on minorities in society such as patients, the elderly, schoolchildren, and women, using access to medicine strategies as we con-tinue to promote treatment and services for MPN patients around the world, ensuring accessibility, affordability, and availability of new drugs, as well as emphasizing and supporting global MPN community activi-ties. We established a comprehensive MPN health education and communication plat-form in Taiwan, Japan, the US, and China, and participated in international academic seminars and local symposiums as part of our contributions to MPN.

Highlights of Supplier Code of Conduct

PharmaEssentia Corporation (referred to as “PharmaEssentia”) is a biopharmaceutical company focused on the research and development of new drugs.

Highlights of EHS Policy

Since its founding, the Company has pursued sustainable growth and fulfilled its corporate social responsibility by actively engaging with stakeholders across the board—from employees, shareholders/investors, and customers to suppliers/contractors, government bodies, and the wider community.

News

Latest Newsletter

2026 / 06 / 12

PharmaEssentia Honored with the 1.5°C Temperature Control Certification

2026 / 05 / 21

PharmaEssentia and Jingming Chemical Advance Sustainable Supply Chain Collaboration

2026 / 05 / 05

PharmaEssentia Included in the Dow Jones Best-in-Class Indices (DJBIC) as Taiwan’s Sole Pharmaceutical and Biotechnology Representative

PharmaEssentia has been selected as a constituent of the Dow Jones Best-in-Class Indices (DJBIC), becoming the sole Taiwanese biopharmaceutical company included in its industry category. This recognition highlights the Company’s commitment to sustainable growth, transparent governance, and long-term stakeholder value creation.

2026 / 04 / 08

From Commitment to Action: Strengthening ESG Governance through Supplier On-site Audits

2026 / 03 / 24

[Sustainability Insights] Participating in the 2026 S&P Global CSA Workshop: Mastering New Assessment Trends and Building Supply Chain Resilience

2026 / 01 / 19

PharmaEssentia Included in

2025 / 12 / 01

Celebrating Excellence: PharmaEssentia Receives Gold Award at 2025 TCSA

2025 / 11 / 17

2025 ACGA Annual Conference: Special Report on Sustainability

2025 / 11 / 03

PharmaEssentia Honored for Excellence in Occupational Health and Safety Disclosure (2025 CSR Evaluation).

Pharmaessentia corp. Recognized by the Ministry of Labor for Excellence in Occupational Health and Safety Performance

Pharmaessentia corp. is honored to receive recognition in the 2025 Occupational Health and Safety Performance Evaluation of Corporate Sustainability Reports, organized by the Occupational Safety and Health Administration (OSHA) under Taiwan’s Ministry of Labor.

This recognition highlights our continuous commitment to creating a safe, healthy, and inclusive workplace.

The evaluation, based on GRI 403: Occupational Health and Safety (2018) and SASB standards, assessed companies across five dimensions-governance, strategy, risk and opportunity, performance, and verification-to promote transparency and best practices in workplace safety disclosure.

This achievement reaffirms Pharmaessentia’s leadership in strengthening occupational health management, enhancing employee well-being, and implementing a responsible and sustainable supply chain.

We will continue advancing workplace sustainability and fostering a culture of safety and care as part of our long-term ESG commitment.

2025 / 06 / 27

PharmaEssentia Awarded the 1.5°C Climate Certification Label

At the “Corporate 1.5°C – Holding the Line on Global Warming Forum” hosted by CommonWealth Magazine

2024 / 11 / 21

PharmaEssentia Achieves Record High Scores in the 2024 S&P Global Sustainability Assessment(UPDATED)

The 99th percentile (Top 1%) of the S&P Global ESG Performance in the global Biotechnology industry

2024 / 10 / 30

PharmaEssentia Achieves Record High Scores in the 2024 S&P Global Sustainability Assessment

Achieved an outstanding score in the social dimension, contributing to healthcare and talent management

2024 / 09 / 25

PharmaEssentia Summer Internship Program: Future Pharmaceutical Professionals to Advance Corporate Sustainability

Aligning with the UN SDGs and Committing to Talent Development and Sustainable Growth

2024 / 08 / 09

PharmaEssentia Partners with NPOs at 2024 SDG Asia Sustainability Salon to Drive Business and ESG Social Impact

Responding to promote "With technology's love, eliminate health inequity" for the SDGs

2024 / 07 / 31

PharmaEssentia Enhances Information Security Management System: Achieves ISO/IEC 27001:2022 International Certification

Achieving ISO/IEC 27001:2022 International Certification Brings Competitive Advantages

2024 / 06 / 28

PharmaEssentia (stock code: 6446) has released "2023 ESG Sustainability Report"

In 2023, ESG performance showcased 46 highlights, demonstrating Authentic and Eternal Value Creating

2024 / 06 / 21

PharmaEssentia Japan Launches a New Support Program for Patients with Polycythemia Vera and Their Families

The "Ashitahe" program launched , aims to help patients face treatment more positively and reduced anxiety

2024 / 05 / 31

PharmaEssentia continues to support MPN patient groups by organizing health education seminars to improve medical care quality

Committing to Access To Medicine, empowering local capacity building, and making a societal impact

2024 / 04 / 30

7th Annual MPN Asia 2024 Takes Place in Osaka, Japan

An Innovative, diverse, and open communication to build community collaboration and win-win outcomes

2024 / 03 / 29

PharmaEssentian US subsidiary team participates in community charity events

To collate “Cheeriodicals” care kits for pediatric patients at the Arnold Palmer Hospital for Children

2024 / 02 / 15

PharmaEssentia Taiwan's premier and sole biotech company selected for the 2024 S&P Global Sustainability Yearbook

In 2023, ESG performance ranked 98 percentile globally within the biotech industry

2024 / 01 / 31

PharmaEssentian officially launched The OHS Committee ,and approved to implement the ISO 45001 international standard

Establish an OHS Committee, train employee’s awareness, contribute to addressing multiple SDGs

2023 / 12 / 25

PharmaEssentia Advances Telehealth in Rural Communities, Introduces AI Digital Care Education at Collaborative Sites

Continuously Caring for the Elderly Vulnerable, Advocating for a Friendly and Inclusive Community

2023 / 11 / 15

PharmaEssentia Clinches Dual Honors in Sustainable Report Awards: Receives TCSA Platinum Award & GCSA Bronze Award

Commended for Deep Commitment to SDG3 and Recognized for Outstanding ESG Achievements

2023 / 10 / 26

PharmaEssentia Announces Entry into 2023~2024 Sustainable Leap Year

Expanding Data Collection, Initiating Double Materiality Principles,and implementing TCFD Scenario Analysis

2023 / 09 / 28

PharmaEssentia ESG Sustainability Center Unveils 2023 ESG Education Training Series

Review Our ESG Journey, and Enhance Resource Allocation Focus and Strengthen Corporate Resilience

2023 / 08 / 31

Stepping Up Environmental Sustainability: PharmaEssentia Taichung Plant Broadens Annual Greenhouse Gas Inspection

Revitalizing Eco-Friendly Environment with the Continuation of the 2022 ISO 14064-1 GHG Inspection Project

2023 / 07 / 21

MPN Asia – Promote Social Inclusion and Sustainable Wellbeing and Healthy Development Goal

2023 Asia-Pacific Sustainability Action Awards -Sustainability Action Award SDG3:Silver

2023 / 07 / 21

Achieves Dual Honors at the 2023 Asia Pacific and Taiwan Sustainable Action Awards, Recognizing its Commitment to Sustainable Health and Social Inclusion

MPN Asia International Annual Conference Won APSAA Silver Award & TSAA Bronze Award

2023 / 07 / 12

PharmaEssentia embraces a culture of workplace safety, aiming to enhance employees' emergency response and first aid capabilities

Protecting workers' rights (SDG8) and establishing a safe and healthy work environment (SDG12)

2023 / 06 / 30

PharmaEssentia (stock code: 6446) has released its 4th-year "2022 Corporate Sustainability Report"

Year of Performance Progress Communication, we presented a total of 51 ESG highlights

2023 / 05 / 30

Reuse Old Computers: Reduce Emissions, Sustain Value

Promoting Environmental Sustainability, SDG 5, SDG 12, and SDG 13

2023 / 04 / 24

PharmaEssentia 2022 Sustainability Report Receives Independent Assurance Statement from Third-Party Verification Agency

Expands Assurance Scope to Overseas and Enhances Reporting with New Indicators and Quantitative Content

2023 / 03 / 16

Improving emergency response capabilities, PharmaEssentia Taipei office has successfully completed the professional training

Creating an efficient emergency response team and ensuring employee safety

2023 / 02 / 24

PharmaEssentia contributed local healthcare capacity building and accelerated healthcare efficiency

2022 / 12 / 21

PharmaEssentia supported Healthy Aging In Place , contributed to Rural Health Promotion Philanthropy

2022 / 12 / 09

PharmaEssentia sponsored Jane Goodall Institute Taiwan to replace refrigerants and reduce carbon emissions

2022 / 11 / 16

PharmaEssentia Won TCSA Platinum Award Chinese Report & Bronze Award English Report by GCSA

2022 / 10 / 25

PharmaEssentia Executive Center for Corporate Sustainability kicks off 2022-2023 ESG meeting and training

More than 100 employees participated proactively for achieving ESG goals of Corporate sustainability

2022 / 10 / 12

PharmaEssentia Health Talk: Office Human Factors Prevention and Stretching

2022 / 09 / 15

PharmaEssentia Climate Governance of Taipei : GHG management and internal verifier education & training

2022 / 09 / 12

PharmaEssentia Health Talk : Keep away from Metabolic Syndrome

2022 / 08 / 02

The Execution Center for Corporate Sustainability hold the first ESG education and training in 2022

2022 / 07 / 25

PharmaEssentia Climate Governance : GHG management and internal verifier education & training

2022 / 06 / 30

PharmaEssentia(6446) earns top ESG scores and announces to release 2021 Sustainability Reports both in English and Chinese simultaneously today

2022 / 06 / 22

PHARMAESSENTIA HONORED AT THE NATIONAL ORGANIZATION OF RARE DISORDERS (NORD®) 2022 RARE IMPACT AWARDS FOR THE INTRODUCTION OF BESREMI® (ROPEGINTERFERON ALFA-2B-NJFT) FOR POLYCYTHEMIA VERA

2022 / 05 / 24

PharmaEssentia Compliance training: IRPMA COP Updates and Remind

2022 / 04 / 27

Pharmaessentia Japan Files Marketing Authorization Application for Ropeginterferon Alfa-2b for the Treatment of Polycythemia Vera

2022 / 04 / 25

PharmaEssentia exercises the cybersecurity and data privacy protection social engineering online education & training

2022 / 04 / 17

Announcement of the Top-line Results of the Phase I clinical trial of KX01 for Actinic Keratosis (AK) in Japan on Behalf of Subsidiary PharmaEssentia Japan KK

2022 / 03 / 29

PharmaEssentia and Chiayi Chang-Geng Memorial Hospital establish the first MPN Center in Taiwan to practice the governance of Access to Medicine

2022 / 03 / 02

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY UPDATE RECOMMENDS BESREMi® (ROPEGINTERFERON ALFA-2B-NJFT) FOR THE TREATMENT OF POLYCYTHEMIA VERA

2022 / 03 / 02

The NCCN Guidelines has included Besremi (Ropeginterferon alfa-2b) as a recommended therapeutic option for Adults with Polycythemia Vera (PV)

2022 / 02 / 25

PharmaEssentia has expanded the diversified perspective and re-identified the stakeholders and the materiality matrix of sustainability topics in the 3rd ESG Year

2022 / 02 / 14

The Company Announces Completion of Application of the

2022 / 01 / 25

PharmaEssentia Legal Risk Talk : Legal Risk Arising from Wrongful and Dishonest Workplace Conduct

2021 / 12 / 01

3rd PharmaEssentia ESG Sustainability Center Kick-Off Meeting and training

2021 / 11 / 17

PharmaEssentia 2020 ESG Sustainability Report Won The First Gold Award

2021 / 10 / 21

PharmaEssentia Health Talk : Cardiovascular Knowledge and Prevention

2021 / 09 / 24

The Execution Center for Corporate Sustainability hold the second ESG education and training in September

2021 / 09 / 16

PharmaEssentia releases English Sustainability Report for 2020 and new ESG Website

2021 / 08 / 31

PharmaEssentia officially launched TCFD (Task Force on Climate-Related Financial Disclosures) education and training today

2021 / 07 / 30

PharmaEssentia published the Sustainability Report and ranked among the top 15% of global biotechnology

Commercial Times, July 30,2021

2021 / 07 / 30

PharmaEssentia grasped the sustainable highlights of ESG and the international sustainability rating has been upgraded

Economy Daily News, July 30,2021

2021 / 07 / 28

PharmaEssentia published the Second Chinese Version of ” 2020 Sustainability Report ” and the New Website of ESG

2021 / 05 / 07

The “ 2020 Sustainability Report ” has obtained the Statement of Independent Assurance Opinion guaranteed by BSI Taiwan

2021 / 04 / 30

The company has sustained to Top 6%~20% range on the 2020 Corporate Governance Evaluation Results

2021 / 03 / 15

Completed the second ESG non-financial risk education and training, identified ESG materiality risk topics and non-financial risk matrix

2021 / 01 / 15

" COSO ERM” was introduced for the first time to conduct the first ESG non-financial risk education and training for the five taskforces team members

2020 / 12 / 30

PharmaEssentia published the First English Version of “ 2019 Sustainability Report ”

2020 / 11 / 30

To optimize the implementation and Improvement of the sustainability project, we launch the second phase of the sustainability blueprint to focus on the connectivity between SDGs and SASB.

2020 / 10 / 15

The Execution Center for Corporate Sustainability introduced "SMART" management principle for the first time to educate and train the five taskforces team members

2020 / 09 / 30

PharmaEssentia published the First Chinese Version of ” 2019 Sustainability Report ”

2020 / 07 / 15

The Execution Center for Corporate Sustainability and five taskforces were formally established to jointly manage materiality of sustainability topics

2020 / 04 / 30

The company has promoted to Top 6%~20% range on the 2019 Corporate Governance Evaluation Results

2020 / 04 / 15

Established the Execution Center for Corporate Sustainability for the first time and completed sustainability training for all employees in five taskforces

2020 / 03 / 16

The first analysis, study and response to Sustainalytics, MSCI sustainability assessment

2020 / 02 / 16

Start the first year of corporate sustainability, and instill 100% of corporate sustainability DNA

2019 / 11 / 15

All directors take a continuing education arrangement on corporate sustainability

2019 / 10 / 15

Launched a 5-year sustainable development strategy and blueprint for the first time

Keep in Touch with Us

Please contact us for any suggestion on the sustainable development of PharmaEssentia.
To learn more about the latest actions of PharmaEssentia’s sustainability project, please subscribe PEC Latest Newsletter monthly or visit us.

Transform our Corporate Culture and Innovation Facilitate Human health, well-being and Sustainability

Bold innovation, Rapid adaptation Strong integrity, Sustainable development